The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BLUE, AZN and XOM
Back to Newsroom
Mentioned in this Article

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BLUE, AZN and XOM

Tuesday, March 2, 2021 1:45 PM
Share this article now
Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / March 2, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

bluebird bio, Inc. (NASDAQ:BLUE)
Class Period: May 11, 2020 - November 4, 2020
Lead Plaintiff Deadline: April 13, 2021

bluebird bio, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) data supporting bluebird's BLA submission for LentiGlobin for SCD was insufficient to demonstrate drug product comparability; (ii) Defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company's BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (iii) as a result of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in BLUE: http://www.kleinstocklaw.com/pslra-1/bluebird-bio-inc-loss-submission-form?id=13238&from=1

Astrazeneca Plc (NYSE:AZN)
Class Period: May 21, 2020 - November 20, 2020
Lead Plaintiff Deadline: March 29, 2021

The AZN lawsuit alleges Astrazeneca Plc made materially false and/or misleading statements and/or failed to disclose during the class period that: (a) initial clinical trials for the Company's COVID-19 vaccine, AZD1222, had suffered from a critical manufacturing error, resulting in a substantial number of trial participants receiving half the designed dosage; (b) clinical trials for AZD1222 consisted of a patchwork of disparate patient subgroups, each with subtly different treatments, undermining the validity and import of the conclusions that could be drawn from the clinical data across these disparate patient populations; (c) certain clinical trial participants for AZD1222 had not received a second dose at the designated time points, but rather received the second dose up to several weeks after the dose had been scheduled to be delivered according to the original trial design; (d) AstraZeneca had failed to include a substantial number of patients over 55 years of age in its clinical trials for AZD1222, despite this patient population being particularly vulnerable to the effects of COVID-19 and thus a high priority target market for the drug; (e) AstraZeneca's clinical trials for AZD1222 had been hamstrung by widespread flaws in design, errors in execution, and a failure to properly coordinate and communicate with regulatory authorities and the general public; (f) as a result of (a)-(e) above, the clinical trials for AZD1222 had not been conducted in accordance with industry best practices and acceptable standards and the data and conclusions that could be derived from the clinical trials was of limited utility; and (g) as a result of (a)-(f) above, AZD1222 was unlikely to be approved for commercial use in the United States in the short term, one of the largest potential markets for the drug.

Learn about your recoverable losses in AZN: http://www.kleinstocklaw.com/pslra-1/astrazeneca-plc-loss-submission-form?id=13238&from=1

Exxon Mobil Corporation (NYSE:XOM)
Class Period: February 28, 2018 - January 14, 2021
Lead Plaintiff Deadline: March 29, 2021

Exxon Mobil Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Exxon forced its employees to use unrealistic assumptions regarding the timelines for well drilling in the Permian Basin; (ii) the foregoing assumptions served to artificially inflate the value of the Company's well operations in the Permian Basin; (iii) the foregoing conduct, when revealed, subjected Exxon to a heightened risk of regulatory investigation and oversight; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in XOM: http://www.kleinstocklaw.com/pslra-1/exxon-mobil-corporation-loss-submission-form?id=13238&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

The Klein Law Firm
Back to Newsroom
Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions